Inhibition of Bruton's Tyrosine Kinase Protects Against Burn Sepsis-Induced Intestinal Injury

Inhibition of Bruton's Tyrosine Kinase Protects Against Burn Sepsis-Induced Intestinal Injury

This study aimed to investigate the role and molecular mechanisms of Bruton's tyrosine kinase (BTK), a member of the Tec family in burn sepsis-induced intestinal injury. Eighty C57BL/6 mice were randomly divided into four groups: the sham group, the burn group, the burn + sepsis group, and the...

Full description

Bibliographic Details
Main Authors:	Jia Wan, Xi Yu, Jia-Qi Niu, Le Qiu, Fei Wang, Xu-Lin Chen
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2022-02-01
Series:	Frontiers in Medicine
Subjects:	Bruton's tyrosine kinase intestinal injury burns sepsis oxidative stress
Online Access:	https://www.frontiersin.org/articles/10.3389/fmed.2022.809289/full

Similar Items

Bruton’s Tyrosine Kinase Inhibitors (BTKIs): Review of Preclinical Studies and Evaluation of Clinical Trials
by: Dariusz Rozkiewicz, et al.
Published: (2023-03-01)

Role of Bruton’s Tyrosine Kinase in Stage III Colorectal Cancer
by: Debora Basile, et al.
Published: (2019-06-01)

Efficacy and safety of Bruton's tyrosine kinase inhibitors in the treatment of pemphigus: A comprehensive literature review and future perspective
by: Yekta Ghane, et al.
Published: (2023-12-01)

The Use of Bruton Tyrosine Kinase Inhibitors in Waldenström’s Macroglobulinemia
by: Obada Ababneh, et al.
Published: (2022-05-01)

A mechanism for localized dynamics-driven activation in Bruton's tyrosine kinase
by: Simei Qiu, et al.
Published: (2021-08-01)

Bruton's Tyrosine Kinase Inhibition Attenuates the Cardiac Dysfunction Caused by Cecal Ligation and Puncture in Mice
by: Caroline E. O'Riordan, et al.
Published: (2019-09-01)

Immunomodulating effects of antitumor drugs Bruton tyrosine kinase inhibitors and the possibility of their use in allergic and infectious diseases
by: Yu. S. Torshina, et al.
Published: (2023-06-01)

The Use of Bruton Tyrosine Kinase Inhibitors in Waldenström’s Macroglobulinemia
by: Abdullah Mohammad Khan
Published: (2022-04-01)

X-Linked Immunodeficient Mice With No Functional Bruton's Tyrosine Kinase Are Protected From Sepsis-Induced Multiple Organ Failure
by: Caroline E. O'Riordan, et al.
Published: (2020-10-01)

Discovery of 5-Phenoxy-2-aminopyridine Derivatives as Potent and Selective Irreversible Inhibitors of Bruton’s Tyrosine Kinase
by: Eun Lee, et al.
Published: (2020-10-01)

"Screening of the Bruton Tyrosine Kinase (BTK) Gene Mutations in 13 Iranian Patients with Presumed X-Linked Agammaglobulinemia "
by: "Asghar Aghamohammadi, et al.
Published: (2004-12-01)

Bruton’s Tyrosine Kinase Targeting in Multiple Myeloma
by: Max Von Suskil, et al.
Published: (2021-05-01)

Bruton’s Tyrosine Kinase Inhibitors: A New Therapeutic Target for the Treatment of SLE?
by: Lorenzo-Vizcaya A, et al.
Published: (2020-06-01)

Bruton Tyrosine Kinase Inhibition and Its Role as an Emerging Treatment in Pemphigus
by: Aikaterini Patsatsi, et al.
Published: (2021-08-01)

Targeting Bruton’s tyrosine kinase in vitreoretinal lymphoma: an open-label, prospective, single-center, phase 2 study
by: Wenxue Guan, et al.
Published: (2022-11-01)

Mutations of Bruton's tyrosine kinase gene in Brazilian patients with X-linked agammaglobulinemia
by: V.D. Ramalho, et al.
Published: (2010-09-01)

Translational autoimmunity in pemphigus and the role of novel Bruton tyrosine kinase inhibitors
by: Piyu Parth Naik
Published: (2022-01-01)

Targeting Bruton Tyrosine Kinase: A novel strategy in the treatment of B-cell lymphomas
by: Sklavenitis-Pistofidis R., et al.
Published: (2017-06-01)

Targeting Multiple End Organs in Lupus and Other Systemic Rheumatic Diseases by Inhibiting Bruton’s Tyrosine Kinase
by: Yong Du, et al.
Published: (2022-07-01)

Design, synthesis and evaluation of a series of potential prodrugs of a Bruton’s tyrosine kinase (BTK) inhibitor
by: Zhou-Peng Xiao, et al.
Published: (2023-03-01)

Non-Covalent Bruton’s Tyrosine Kinase Inhibitors in the Treatment of Chronic Lymphocytic Leukemia
by: Skye Montoya, et al.
Published: (2023-07-01)

Bruton’s Tyrosine Kinase Inhibitors: A New Generation of Promising Agents for Multiple Sclerosis Therapy
by: Antonio García-Merino
Published: (2021-09-01)

Bruton’s Tyrosine Kinase Supports Gut Mucosal Immunity and Commensal Microbiome Recognition in Autoimmune Arthritis
by: Rachel H. Bonami, et al.
Published: (2022-03-01)

Bruton’s Tyrosine Kinase-Mediated Signaling in Myeloid Cells Is Required for Protective Innate Immunity During Pneumococcal Pneumonia
by: Alexander P. de Porto, et al.
Published: (2021-09-01)

Pseudomonas aeruginosa sepsis presenting as oral ecthyma gangrenosum in identical twins with Bruton tyrosine kinase gene mutation: Two case reports and review of the literature
by: Sheng-Chieh Lin, et al.
Published: (2020-12-01)

Bruton’s tyrosine kinase-bearing B cells and microglia in neuromyelitis optica spectrum disorder
by: Ye Liu, et al.
Published: (2023-12-01)

Covalent cysteine targeting of Bruton’s tyrosine kinase (BTK) family by withaferin-A reduces survival of glucocorticoid-resistant multiple myeloma MM1 cells
by: Logie, Emilie, et al.
Published: (2021)

The Possible Role of Bruton Tyrosine Kinase Inhibitors in the Treatment of COVID-19: A Review
by: Mitra Rezaei, MD, et al.
Published: (2022-01-01)

Bruton tyrosine kinase inhibitors as potential therapeutic agents for COVID-19: A review
by: Zemene Demelash Kifle
Published: (2021-09-01)

Targeting Bruton’s Tyrosine Kinase in Inflammatory and Autoimmune Pathologies
by: Stefan F. H. Neys, et al.
Published: (2021-06-01)

Inhibition of Bruton Tyrosine Kinase Reduces Neuroimmune Cascade and Promotes Recovery after Spinal Cord Injury
by: Chen Guang Yu, et al.
Published: (2021-12-01)

Bruton’s Tyrosine Kinase in Neutrophils Is Crucial for Host Defense against Klebsiella pneumoniae
by: Zhe Liu, et al.
Published: (2022-05-01)

Specific Expression of a New Bruton Tyrosine Kinase Isoform (p65BTK) in the Glioblastoma Gemistocytic Histotype
by: Luca Sala, et al.
Published: (2019-01-01)

The Evolution of Therapies Targeting Bruton Tyrosine Kinase for the Treatment of Chronic Lymphocytic Leukaemia: Future Perspectives
by: Toby A. Eyre, et al.
Published: (2023-05-01)

Bruton’s Tyrosine Kinase: An Emerging Key Player in Innate Immunity
by: Alexander N. R. Weber, et al.
Published: (2017-11-01)

Comparison of Intermolecular Interactions of Irreversible and Reversible Inhibitors with Bruton’s Tyrosine Kinase via Molecular Dynamics Simulations
by: Xiangfan Yu, et al.
Published: (2022-11-01)

A novel Bruton's tyrosine kinase inhibitor JDB175 shows potent efficacy to suppress central nervous system lymphoma
by: Yong Xia, et al.
Published: (2023-12-01)

Bruton’s tyrosine kinase inhibition limits endotoxic shock by suppressing IL-6 production by marginal zone B cells in mice
by: Kazuhiko Kawata, et al.
Published: (2024-04-01)

ZYBT1, a potent, irreversible Bruton’s Tyrosine Kinase (BTK) inhibitor that inhibits the C481S BTK with profound efficacy against arthritis and cancer
by: Krishnarup Ghoshdastidar, et al.
Published: (2020-08-01)

Observations on the use of Bruton’s tyrosine kinase inhibitors in SAR-CoV-2 and cancer
by: Brooke Benner, et al.
Published: (2021-01-01)